Last reviewed · How we verify
Intramuscular injection of TAK-850
Intramuscular injection of TAK-850 is a Small molecule drug developed by Takeda. It is currently in Phase 1 development.
At a glance
| Generic name | Intramuscular injection of TAK-850 |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants (PHASE1, PHASE2)
- Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults (PHASE1, PHASE2)
- A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intramuscular injection of TAK-850 CI brief — competitive landscape report
- Intramuscular injection of TAK-850 updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Intramuscular injection of TAK-850
What is Intramuscular injection of TAK-850?
Intramuscular injection of TAK-850 is a Small molecule drug developed by Takeda.
Who makes Intramuscular injection of TAK-850?
Intramuscular injection of TAK-850 is developed by Takeda (see full Takeda pipeline at /company/takeda).
What development phase is Intramuscular injection of TAK-850 in?
Intramuscular injection of TAK-850 is in Phase 1.
Related
- Manufacturer: Takeda — full pipeline